<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04324541</url>
  </required_header>
  <id_info>
    <org_study_id>2019-192</org_study_id>
    <nct_id>NCT04324541</nct_id>
  </id_info>
  <brief_title>Health &amp; Aging Brain Study: Health Disparities TAU Project</brief_title>
  <official_title>Health &amp; Aging Brain Study: Health Disparities TAU Project</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sid E. O'Bryant</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of North Texas Health Science Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
  </oversight_info>
  <brief_summary>
    <textblock>
      By doing this study we are trying to learn more about brain aging in Mexican Americans.

      Participants will be asked to complete a screening visit to determine if it is safe to
      undergo a PET scan.

      If eligible, participants will undergo a medical procedure that takes a picture of their
      brain. This procedure is called a PET scan of the brain.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">September 23, 2019</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Presence or absence of Tau in the brain as measured by PET imaging</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Brain Aging in Mexican Americans</condition>
  <arm_group>
    <arm_group_label>Mexican American Adults</arm_group_label>
    <description>No intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>PET scan of the brain with Flortaucipir</intervention_name>
    <description>PET scan of the brain with non FDA approved Radio tracer.</description>
    <arm_group_label>Mexican American Adults</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Mexican Americans that participated in the Health &amp; Aging Brain Study Amyloid Project
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participation in the Health &amp; Aging Brain Study: Health Disparities Amyloid Project

        Exclusion Criteria:

          -  Not a participant in the Health &amp; Aging Brain Study: Health Disparites Amyloid Project

          -  Medical condition that precludes safe use of PET tracer
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of North Texas Health Science Center Institute for Translational Research</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 24, 2020</study_first_submitted>
  <study_first_submitted_qc>March 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 27, 2020</study_first_posted>
  <last_update_submitted>March 26, 2020</last_update_submitted>
  <last_update_submitted_qc>March 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of North Texas Health Science Center</investigator_affiliation>
    <investigator_full_name>Sid E. O'Bryant</investigator_full_name>
    <investigator_title>Executive Director, Institute for Translational Research Professor, Department of Pharmacology &amp; Neuroscience</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

